Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.45 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.45 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.45 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.45 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.45 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.45 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.44 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.43 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.43 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.42 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27539616 | 1.00 | LMNA (0.56) | LMNAHSD17B10MAPTPOLBPKM | |
| SCHEMBL701147 | 0.98 | LMNA (0.58) | LMNAHSD17B10MAPTPOLBPKM | |
| SCHEMBL380364 | 0.81 | HSD17B10 (0.56) | LMNAHSD17B10MAPTCYP2C9SMN1; SMN2 | |
| SCHEMBL7781973 | 0.80 | HSD17B10 (0.50) | LMNAHSD17B10MAPTPOLBCYP2C9 | |
| SCHEMBL269329 | 0.80 | LMNA (0.80) | LMNAHSD17B10MAPTPOLBPKM | |
| SCHEMBL2625475 | 0.78 | ELANE (0.60) | LMNAHSD17B10CYP2C9SMN1; SMN2CYP1A2 | |
| SCHEMBL18727667 | 0.78 | HSD17B10 (0.58) | LMNAHSD17B10CYP2C9SMN1; SMN2CYP1A2 | |
| Lithium SCHEMBL30522746 | 0.78 | LMNA (0.76) | LMNAHSD17B10MAPTPOLBPKM | |
| SCHEMBL14760365 | 0.78 | LMNA (0.76) | LMNAHSD17B10MAPTPOLBPKM | |
| Hydrochloric Acid SCHEMBL10772752 | 0.77 | HSD17B10 (0.52) | LMNAHSD17B10MAPTCYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582423-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024080788-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | 한미약품 주식회사 | 2024-04-18 | — | — | WO | disclosed |
| CN-116059390-A | Prodrugs of cytotoxic actives with enzymatically cleavable groups | 拜耳制药股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-110312533-A | Prodrugs of cytotoxic active agents having an enzymatically cleavable group | 拜耳公司 | 2019-10-08 | — | — | CN | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| CN-108883195-A | Prodrugs of cytotoxic active substances with enzymatically cleavable groups | 拜耳制药股份公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-104428293-B | Adjust the benzimidazole of TNF α | UCB生物制药私人有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-107921288-A | The targeting conjugate of KSP inhibitor | 拜耳医药股份有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-104428293-A | TNF -alpha modulating benzimidazoles | UCB PHARMA SA | 2015-03-18 | — | — | CN | disclosed |
| US-8530650-B2 | 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer | MERCK PATENT GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| CN-1020104-C | Process for preparing 3-propenyl cephem derivatives | EISAI CO LTD (JP) | 1993-03-17 | — | — | CN | disclosed |
| US-5089491-A | Active against both gram-negative and gram-positive bacteria | EISAI CO., LTD. (JP) | 1992-02-18 | — | — | US | disclosed |
| EP-0264091-B1 | 3-PROPENYLCEPHEM DERIVATIVE, PREPARATION THEREOF, CHEMICAL INTERMEDIATES THEREIN, PHARMACEUTICAL COMPOSITION AND USE | Eisai Co., Ltd. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-5066812-A | Chemical intermediates for bactericides | EISAI CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| US-5006649-A | Bactericides | EISAI, CO. (JP) | 1991-04-09 | — | — | US | disclosed |
| US-4921850-A | GRAMNEGATIVE AND GRAMPOSITIVE BACTERICIDE | EISAI CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| US-4797411-A | ANTITUMOR AGENTS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1989-01-10 | — | — | US | disclosed |
| CN-87107610-A | Process for the preparation of cephem derivatives and intermediates therefor | — | 1988-06-01 | — | — | CN | disclosed |
| EP-0264091-A2 | 3-Propenylcephem derivative, preparation thereof, chemical intermediates therein, pharmaceutical composition and use | Eisai Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| EP-0253681-A2 | Cycloalkyl-substituted 4-pyridyl derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-01-20 | — | — | EP | disclosed |